{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"50.10","upperLimit":"93.19","value":"76.5"},{"groupId":"OG001","lowerLimit":"0.00","upperLimit":"70.76","value":"0.0"},{"groupId":"OG002","lowerLimit":"40.78","upperLimit":"84.61","value":"65.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"20"}],"units":"Participants"}],"title":"Wk48:GH: >= 1 - <= 2.5 μg/L at screen."},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"44.04","upperLimit":"89.69","value":"70.6"},{"groupId":"OG001","lowerLimit":"0.00","upperLimit":"70.76","value":"0.0"},{"groupId":"OG002","lowerLimit":"36.05","upperLimit":"80.88","value":"60.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"20"}],"units":"Participants"}],"title":"Wk60:GH: >= 1 - <= 2.5 μg/L at screen."},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"38.33","upperLimit":"85.79","value":"64.7"},{"groupId":"OG001","lowerLimit":"0.00","upperLimit":"70.76","value":"0.0"},{"groupId":"OG002","lowerLimit":"31.53","upperLimit":"76.94","value":"55.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"20"}],"units":"Participants"}],"title":"Wk72:GH: >= 1 - <= 2.5 μg/L at screen."},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.91","upperLimit":"22.93","value":"11.9"},{"groupId":"OG001","lowerLimit":"0.28","upperLimit":"48.25","value":"11.1"},{"groupId":"OG002","lowerLimit":"5.22","upperLimit":"21.87","value":"11.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"68"}],"units":"Participants"}],"title":"Wk48: GH: > 2.5 μg/L at screening"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.91","upperLimit":"22.93","value":"11.9"},{"groupId":"OG001","lowerLimit":"0.00","upperLimit":"33.63","value":"0.0"},{"groupId":"OG002","lowerLimit":"4.24","upperLimit":"20.07","value":"10.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"68"}],"units":"Participants"}],"title":"Wk60: GH: > 2.5 μg/L at screening"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.91","upperLimit":"22.93","value":"11.9"},{"groupId":"OG001","lowerLimit":"0.00","upperLimit":"33.63","value":"0.0"},{"groupId":"OG002","lowerLimit":"4.24","upperLimit":"20.07","value":"10.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"68"}],"units":"Participants"}],"title":"Wk72: GH: > 2.5 μg/L at screening"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.87","upperLimit":"37.68","value":"26.3"},{"groupId":"OG001","lowerLimit":"0.21","upperLimit":"38.48","value":"8.3"},{"groupId":"OG002","lowerLimit":"15.42","upperLimit":"34.14","value":"23.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"88"}],"units":"Participants"}],"title":"Week 48: Pasireotide LAR overall"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.77","upperLimit":"36.26","value":"25.0"},{"groupId":"OG001","lowerLimit":"0.00","upperLimit":"26.46","value":"0.0"},{"groupId":"OG002","lowerLimit":"13.53","upperLimit":"31.65","value":"21.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"88"}],"units":"Participants"}],"title":"Week 60: Pasireotide LAR overall"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.68","upperLimit":"34.82","value":"23.7"},{"groupId":"OG001","lowerLimit":"0.00","upperLimit":"26.46","value":"0.0"},{"groupId":"OG002","lowerLimit":"12.60","upperLimit":"30.39","value":"20.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"88"}],"units":"Participants"}],"title":"Week 72: Pasireotide LAR overall"}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"88"}],"units":"Participants"}],"description":"Percentage of patients achieving GH \\<1 μg/L and IGF-1 \\<ULN at week 48 by treatment with pasireotide LAR alone or with concomitant medications used to treat acromegaly","dispersionType":"95% Confidence Interval","groups":[{"description":"These Participants were treated with pasireotide LAR only in the extension phase","id":"OG000","title":"Pasireotide LAR Monotherapy"},{"description":"These Participants were treated with pasireotide LAR as well as other concomitant medications in the extension phase","id":"OG001","title":"Pasireotide With Concomitant Mediaction"},{"description":"This is the sum total of participants who were treated with at least one dose of pasireotide LAR in the extension phase","id":"OG002","title":"Pasireotide LAR Overall"}],"paramType":"NUMBER","populationDescription":"Extension FAS included all the patients who received at least one dose of pasireotide LAR in the extension phase.","reportingStatus":"POSTED","timeFrame":"Weeks 48, 60, 72","title":"Extension Phase: Percentage of Participants With Mean GH < 1 μg/L at Weeks 48, 60, 72 and Overall, Pasireotide Montherapy and Pasireotide With Concomittant Medication and by GH Level at Screening","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}